Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2013 / Cilt: 23 - Sayı: 2

Malign ve Benign Plevral Hastalıkların Ayırıcı Tanısında 18-FDG PET/BT’nin Etkinliği

Accuracy of 18-FDG PET/CT in the Differential Diagnosis of Malignant and Benign Pleural Diseases

Pages
124–129
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall sensitivity,specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET/CT was 81.8%, 54.5%, 64.3%, 75%, and 68.2% for pleural thickening and it was 100%, 56.5%, 41.1%, 100%, and 60% for patients with pleural fluid.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Integrated whole-body 18-fluorodeoxyglucose positron emission tomography-computed tomography (PET/CT) is a non-invasive imaging technique for identifying several types of malignant diseases.
📊
Key Findings & Data:Maximum standardized uptake values (SUVmax) were calculated separately for pleural thickening and pleural fluid and compared with pathological results obtained by video thoracoscopy.
💡
Conclusion & Impact:The overall sensitivity,specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET/CT was 81.8%, 54.5%, 64.3%, 75%, and 68.2% for pleural thickening and it was 100%, 56.5%, 41.1%, 100%, and 60% for patients with pleural fluid.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Integrated whole-body 18-fluorodeoxyglucose positron emission tomography-computed tomography (PET/CT) is a non-invasive imaging technique for identifying several types of malignant diseases. We evaluated the role of PET/CT in distinguishing malignant from benign pleural diseases. Thirty patients, who had pleural abnormalities on computed tomography (CT), such as thickening, fluid with suspicion of malignant pleural mesothelioma or any other malignancy underwent PET/CT. Maximum standardized uptake values (SUVmax) were calculated separately for pleural thickening and pleural fluid and compared with pathological results obtained by video thoracoscopy. Twenty-two patients with pleural thickening and 25 patients with pleural fluid were assessed with regard to the accuracy of PET/CT. The overall sensitivity,specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET/CT was 81.8%, 54.5%, 64.3%, 75%, and 68.2% for pleural thickening and it was 100%, 56.5%, 41.1%, 100%, and 60% for patients with pleural fluid. When the pleural thickening was evaluated, the SUVmax values were higher in the malignant pleural diseases than in the benign pleural diseases but the difference was not statistically significantly (p = 0.063). When the pleural fluid was evaluated, the SUVmax values were also higher in the malignant pleural diseases than in the benign pleural diseases and the difference was statistically significantly (p= 0.03). The accuracy of PET/CT for detecting malignant pleural fluids was high. However, PET/CT was not adequate to make the differential diagnosis of pleural malignancies especially in case of pleural thickening because of its relatively low sensitivity,specificity,PPV, and NPV. A tissue biopsy is necessary to determine the diagnosis.

Özet

Tüm vücut 18-florodeoksiglukoz pozitron emisyon tomografi /bilgisayarlı tomografisi (PET / BT) birçok malign hastalığın tanısında kullanılan non-invaziv bir hibrid görüntüleme tekniğidir. Çalışmamızda malign ve benign plevral hastalıkların ayırıcı tanısında PET / BT’nin etkinliği değerlendirildi. Bilgisayarlı tomografide malign plevral mezotelyoma ve diğer malignite şüphesi oluşturan plevral kalınlaşma veya plevral sıvısı saptanan 30 hastaya PET / BT uygulandı. SUVmax değerleri plevral kalınlaşma ve plevral sıvı için ayrı ayrı hesaplanarak video torakoskopi ile elde edilen patoloji sonuçları ile karşılaştırıldı. Plevral kalınlaşması olan 22 hasta ve plevral sıvısı olan 25 hasta PET / BT etkinliği açısından değerlendirildi. Plevral kalınlaşma için duyarlılık, özgüllük, pozitif prediktif değer (PPV), negatif prediktif değeri (NPD) ve PET / BT’nin etkinlik oranı sırasıyla %81.8, %54.5, %64.3, %75 ve %68.2, plevra sıvı için sırasıyla %100, %56.5, %41.1, %100 ve %60 idi. Plevral kalınlaşma için bakıldığında SUVmax değerleri malign hastalarda daha yüksek olmakla beraber aradaki fark istatistiksel olarak anlamlı değildi (p= 0.063) Plevral sıvı için bakıldığında SUVmax değerleri malign hastalarda daha yüksek bulundu ve aradaki fark istatistiksel olarak anlamlı bulundu (p= 0.03). Malign plevral sıvıları saptamada PET / BT etkinliği oldukça yüksektir ancak, düşük duyarlılık, özgüllük, PPV ve NPV değerleri özellikle plevral kalınlaşma durumunda plevral malignitelerin ayırıcı tanısı için yeterli değildir. Kesin tanının belirlenmesinde doku biyopsisi mutlak surette gereklidir.

🔖

Cite This Article

CEYLAN, K. C., AKPINAR, D., KAYA, S. O., KOPARAL, H., ÇIRAK, A. K. (2013). Malign ve Benign Plevral Hastalıkların Ayırıcı Tanısında 18-FDG PET/BT’nin Etkinliği. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 23 - Sayı: 2, 124–129. https://ajindex.com/articles/323309

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117: 54-63, 1999
  2. Kramer H, Pieterman RM, Slebos D, et al. PET for the Evaluation of Pleural Thickening Observed on CT. J Nucl Med 6: 995-998, 2004
  3. Bruno A, Spini A, Zangheri B. Characterization of pleural mesothelioma: Diagnostic and prognostic value of FDG-PET. J Nucl Med 48: 356, 2007
  4. Yamamoto Y, Nishiyama Y, Gotoh M, et al. FDG PET in the evaluation of malignant pleural mesothelioma. J Nucl Med 47: 475, 2006
  5. Caretta A, Landoni C, Melloni G, et al. 18-FDG PET in Evaluation of Malignant Pleural Diseases. Eur J Cardiothorac Surg 17: 377-383, 2000
  6. Orki A, Ak›n O, Tasc› E, et al. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg 57: 217-221, 2009
  7. Duysinx B, Corhay JL, Nguyen D, Louis R. How to explore a pleural diseases? Rey Med Liege 63: 615- 623, 2008
  8. Gill RR. Imaging of mesothelioma. Recent Results Cancer Res 189: 27-43, 2011
  9. Scheider DB, Clary-Macy C, Challa S, et al. Positron Emission Tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 120: 128-133, 2000
  10. Erasmus J, Truong MT, Smythe WR, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma:Staging implications. J Thorac Cardiovasc Surg 129: 1364-1370, 2005
  11. Kim BS, Kim IJ, Kim SJ, Kim K. Predictive value of F- 18 FDG PET/CT for malignant pleural effusion in nonsmall cell lung cancer patients. Onkologie 34: 298- 303, 2011
  12. Alkhawaldeh K, Biersack HJ, Henke A, Ezziddin S. Impact daul-time-point F-18 FDG PET/CT in assessment of pleural effusions in patients non-small cell lung cancer. Clin Nuc Med 36: 423-428, 2011
  13. Gupta NC, Rogers JS, Graeber GM, et al. Clinical of F- 18 flourodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malign pleural effusion. Chest 122: 1918-1924, 2002
  14. Erasmus JJ, Mcadams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with non small cell lung cancer. AJR Am J Roentgenol 175: 245-249, 2000
  15. Schaffler GJ, Wolf G, Schoellnast H, Groell R, et al.